You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is A 60-year-old male patient presented to OPD with right upper quadrant abdominal pain, jaundice, fever with a significant history of weight loss, loss of appetite and lethargy. On examination a mass was palpable in the right hypochondrium which was firm in consistency and about 5x5 cm on palpation along with severe hepatomegaly. On seeing the previous records, patient was found to be a known case of Hepatitis C and was on medication for the same. Lab studies, Raised AFP levels Hypercalcemia Erythrocytosis No cirrhotic changes were evident on USG abdomen. Triple phase CT, Liver biopsy were performed. . Which of the following drug has been approved for the above condition: - Sorafenib Imatinib Dasatinib Regorafenib Ramucirumab and explain in detail?
This is a case of hepatocellular carcinoma. HPE image shows malignant hepatocytes growing in distoed versions of normal architecture. The aerial phase in triple phase CT shows a large enhancing lesion suggestive of hepatocellular carcinoma. Imatinib and Dasatinib are tyrosine kinase inhibitors approved for CML.